ID   DM-3
AC   CVCL_2019
SY   DM3
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473059
DR   BioSample; SAMN10988453
DR   Cell_Model_Passport; SIDM01505
DR   DepMap; ACH-000742
DR   DSMZ; ACC-595
DR   DSMZCellDive; ACC-595
DR   IARC_TP53; 30031
DR   LiGeA; CCLE_782
DR   PharmacoDB; DM3_295_2019
DR   Progenetix; CVCL_2019
DR   Wikidata; Q54831188
RX   DOI=10.1101/166199;
RX   PubMed=15372243;
RX   PubMed=23840376;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=33567673;
CC   Problematic cell line: May be misclassified. While still annotated as a pleural sarcomatoid mesothelioma cell line, a variety of omics methods are classifying this cell line as a fibroblast (DOI=10.1101/166199; DepMap).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 54 hours (PubMed=23840376); ~50-60 hours (DSMZ=ACC-595).
CC   HLA typing: A*02:14,02:14; B*13:02,50:01; C*06:02,06:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg496Leu (c.1487G>T); Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0.58%; East Asian, South=0.68%; South Asian=2.16%; European, North=58.64%; European, South=37.94% (PubMed=30894373).
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 9,13
ST   D18S51: 12,15
ST   D19S433: 13,14
ST   D21S11: 29,30
ST   D2S1338: 17,18
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 11,15
ST   FGA: 19,20
ST   Penta D: 11,12
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C45663; Pleural sarcomatoid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 24
RX   DOI=10.1101/166199;
RA   de Weck A., Bitter H., Kauffmann A.;
RT   "Fibroblasts cell lines misclassified as cancer cell lines.";
RL   bioRxiv 2017:166199-166199(2017).
RX   PubMed=15372243; DOI=10.1007/s00418-004-0701-1;
RA   Philippeaux M.-M., Pache J.-C., Dahoun S., Barnet M., Robert J.-H.,
RA   Mauel J., Spiliopoulos A.;
RT   "Establishment of permanent cell lines purified from human
RT   mesothelioma: morphological aspects, new marker expression and
RT   karyotypic analysis.";
RL   Histochem. Cell Biol. 122:249-260(2004).
RX   PubMed=23840376; DOI=10.1371/journal.pone.0065903;
RA   Szulkin A., Nilsonne G., Mundt F., Wasik A.M., Souri P., Hjerpe A.,
RA   Dobra K.;
RT   "Variation in drug sensitivity of malignant mesothelioma cell lines
RT   with substantial effects of selenite and bortezomib, highlights need
RT   for individualized therapy.";
RL   PLoS ONE 8:E65903-E65903(2013).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=33567673; DOI=10.3390/cancers13040685;
RA   Keller M., Reis K., Hjerpe A., Dobra K., Aspenstrom P.;
RT   "Cytoskeletal organization correlates to motility and invasiveness of
RT   malignant mesothelioma cells.";
RL   Cancers (Basel) 13:685.1-685.20(2021).